Success Metrics

Clinical Success Rate
94.3%

Based on 33 completed trials

Completion Rate
94%(33/35)
Active Trials
1(2%)
Results Posted
21%(7 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_1
4
9%
Ph phase_3
8
17%
Ph not_applicable
5
11%
Ph phase_4
19
40%
Ph phase_2
8
17%

Phase Distribution

4

Early Stage

8

Mid Stage

27

Late Stage

Phase Distribution44 total trials
Phase 1Safety & dosage
4(9.1%)
Phase 2Efficacy & side effects
8(18.2%)
Phase 3Large-scale testing
8(18.2%)
Phase 4Post-market surveillance
19(43.2%)
N/ANon-phased studies
5(11.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.8%

33 of 38 finished

Non-Completion Rate

13.2%

5 ended early

Currently Active

1

trials recruiting

Total Trials

47

all time

Status Distribution
Active(2)
Completed(33)
Terminated(5)
Other(7)

Detailed Status

Completed33
unknown7
Withdrawn3
Terminated2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
47
Active
1
Success Rate
94.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (9.1%)
Phase 28 (18.2%)
Phase 38 (18.2%)
Phase 419 (43.2%)
N/A5 (11.4%)

Trials by Status

not_yet_recruiting12%
recruiting12%
terminated24%
unknown715%
withdrawn36%
completed3370%

Recent Activity

Clinical Trials (47)

Showing 20 of 47 trialsScroll for more
NCT07661030Phase 4

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time

Not Yet Recruiting
NCT07370532Phase 2

Etoricoxib in Patients With Parkinsonian Disease

Recruiting
NCT06001112Not Applicable

Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis

Completed
NCT01327638

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Completed
NCT02503839Phase 1

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

Completed
NCT01077843

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Completed
NCT01685424

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Completed
NCT01429168Phase 4

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Withdrawn
NCT04565600Phase 2

Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Completed
NCT00264147Phase 2

Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

Completed
NCT01462370Phase 3

Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)

Completed
NCT00945035Phase 1

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Completed
NCT00757627Phase 4

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Completed
NCT01067430Phase 4

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Withdrawn
NCT03011905Phase 3

Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block

Completed
NCT04462666Phase 2

Oral Huzhang Granules for Acute Gouty Arthritis

Unknown
NCT04144101Phase 4

Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis

Completed
NCT01190722Phase 4

A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain

Withdrawn
NCT02954484Phase 3

Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty

Completed
NCT01300780Not Applicable

Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching

Completed

Drug Details

Intervention Type
DRUG
Total Trials
47